Literature DB >> 8159305

Mediators of complement-independent granulocyte activation during haemodialysis: role of calcium, prostaglandins and leukotrienes.

J Böhler1, J Donauer, M Birmelin, P J Schollmeyer, W H Hörl.   

Abstract

Granulocyte activation during haemodialysis using cuprophane membrane is mediated by complement-derived anaphylatoxins C3a and C5a. However, neutrophil degranulation induced by modified cellulosic membranes or synthetic membranes does not correlate with C3a or C5a concentrations. Incubation and recirculation experiments were performed to find out which messengers trigger neutrophil degranulation during blood contact with different membrane materials. During in vitro haemodialysis for 2 hours, PMMA and cuprophane induced pronounced degranulation of neutrophils. With PMMA this was associated with increased thromboxane B2 but low C3a levels, while with cuprophane membrane, marked complement activation but only little thromboxane B2 release was observed. Indomethacin (10 microM) nullified all thromboxane B2 response but could not influence elastase release, indicating that cyclo-oxygenase products are not involved in neutrophil degranulation under these conditions. During incubation of blood with dialysis membranes, inhibition of lipoxygenase by esculetin or of phospholipase A2 by hydrocortisone also had no effect on neutrophil degranulation. One messenger involved in granulocyte activation might be free cytosolic calcium. Application of different calcium channel blockers (verapamil, diltiazem, or nitrendipine) did not influence neutrophil degranulation in incubation experiments, in PMMA or cuprophane membranes. In contrast, chelation of plasmatic calcium by sodium citrate or EDTA blunted elastase release induced by these membranes. This study indicates that calcium is a key mediator required for neutrophil degranulation in complement-activating and non-complement-activating dialysis membranes, while activation of the prostaglandin or leukotriene cascade are not required.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8159305

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  5 in total

1.  Plasma calprotectin in chronically dialyzed end-stage renal disease patients.

Authors:  Karin Malícková; Helena Brodská; Jana Lachmanová; Sylvie Dusilová Sulková; Ivana Janatková; Helena Marecková; Vladimír Tesar; Tomás Zima
Journal:  Inflamm Res       Date:  2009-10-25       Impact factor: 4.575

Review 2.  Clinical review: anticoagulation for continuous renal replacement therapy--heparin or citrate?

Authors:  Heleen M Oudemans-van Straaten; John A Kellum; Rinaldo Bellomo
Journal:  Crit Care       Date:  2011-01-24       Impact factor: 9.097

3.  Hemofiltration induces generation of leukocyte-derived CD31+/CD41- microvesicles in sepsis.

Authors:  Georg Franz Lehner; Ulrich Harler; Clemens Feistritzer; Viktoria Maria Haller; Julia Hasslacher; Romuald Bellmann; Michael Joannidis
Journal:  Ann Intensive Care       Date:  2017-09-04       Impact factor: 6.925

4.  The predictive role of serum calprotectin on mortality in hemodialysis patients with high phosphoremia.

Authors:  Tomoko Kanki; Takashige Kuwabara; Jun Morinaga; Hirotaka Fukami; Shuro Umemoto; Daisuke Fujimoto; Teruhiko Mizumoto; Manabu Hayata; Yutaka Kakizoe; Yuichiro Izumi; Saeko Tajiri; Tetsuya Tajiri; Kenichiro Kitamura; Masashi Mukoyama
Journal:  BMC Nephrol       Date:  2020-05-04       Impact factor: 2.388

5.  Citrate confers less filter-induced complement activation and neutrophil degranulation than heparin when used for anticoagulation during continuous venovenous haemofiltration in critically ill patients.

Authors:  Louise Schilder; S Azam Nurmohamed; Pieter M ter Wee; Nanne J Paauw; Armand R J Girbes; Albertus Beishuizen; Robert H J Beelen; A B Johan Groeneveld
Journal:  BMC Nephrol       Date:  2014-01-17       Impact factor: 2.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.